KC-5570

BaF3-SLC34A2-ROS1-Luc2 Cell Line

×
Please enable JavaScript in your browser to complete this form.
56839
Home » 细胞系 » BaF3-SLC34A2-ROS1-Luc2 Cell Line

Background of BaF3-SLC34A2-ROS1-Luc2 Cell Line

ROS1 is a receptor tyrosine kinase of the insulin receptor family, the overexpression of overactivity of ROS1 fusion proteins, due to chromosomal rearrangement, are associated with variety of cancers, including glioblastomas, lung cancer. The identification of ROS1 fusion genes as driver genes have broaden the anticancer indication of variety of the inhibitors of other targets, such as Crizotinib, Alectinib, Ceritinib and Brigatinib, which can also inhibit the activation of ROS1.
Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.

Specifications

Catalog NumberKC-5570
Cell Line NameBaF3-SLC34A2-ROS1-Luc2 Cell Line
Host Cell LineBa/F3
DescriptionStable Ba/F3-Luc2 clone expressing exogenous SLC34A2-ROS1 in ROS1 part.
QuantityTwo vials of frozen cells (≥2-106/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10%FBS
Selection MarkerPuromycin
MorphologyMostly single, round (some polymorph) cells in suspension
SubcultureSplit saturated culture 1:10 every 3 days; seed out at about 1-3 × 105 cells/mL
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 30 hours
Mycoplasma StatusNegative

Cell Line Generation

BaF3-SLC34A2-ROS1-luc2 cell Line was generated using retrovirus vector expressing SLC34A2-ROS1 sequence.

Characterization

Figure 1: Characterization of SLC34A2-ROS1 mutation in the Ba/F3-Luc2 stable clone using PCR sequencing.

Figure2: Characterization of the BaF3-SLC34A2-ROS1-Luc2 cell line stable clone using Bright-Lite Luciferase Assay System in the conditions of different cell number.

Cell Resuscitation

1. Prewarm culture medium (RPMI1640 supplemented with 10% FBS)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO2 incubator.
8. Split saturated culture 1:10 every 3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% RPMI-1640 + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

References

1.Gainor, J. F. & Shaw, A. T. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. The Oncologist 18, 865ÿ875 (2013).
2.Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863ÿ870 (2012).
3.Zou, H. Y. et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA 112, 3493ÿ3498 (2015).
Please enable JavaScript in your browser to complete this form.